CN115698059A - 使用抗bet v 1抗体治疗过敏的方法 - Google Patents

使用抗bet v 1抗体治疗过敏的方法 Download PDF

Info

Publication number
CN115698059A
CN115698059A CN202180043390.9A CN202180043390A CN115698059A CN 115698059 A CN115698059 A CN 115698059A CN 202180043390 A CN202180043390 A CN 202180043390A CN 115698059 A CN115698059 A CN 115698059A
Authority
CN
China
Prior art keywords
seq
amino acid
bet
acid sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043390.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·阿塔纳西奥
G·赫尔曼
M·P·奥布莱恩
J·M·奥伦戈
L·佩利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN115698059A publication Critical patent/CN115698059A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180043390.9A 2020-07-01 2021-06-30 使用抗bet v 1抗体治疗过敏的方法 Pending CN115698059A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US63/047,126 2020-07-01
US202063129253P 2020-12-22 2020-12-22
US63/129,253 2020-12-22
PCT/US2021/039945 WO2022006305A1 (en) 2020-07-01 2021-06-30 Methods of treating allergy using anti-bet v 1 antibodies

Publications (1)

Publication Number Publication Date
CN115698059A true CN115698059A (zh) 2023-02-03

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043390.9A Pending CN115698059A (zh) 2020-07-01 2021-06-30 使用抗bet v 1抗体治疗过敏的方法

Country Status (12)

Country Link
US (2) US11897945B2 (cg-RX-API-DMAC7.html)
EP (1) EP4175986A1 (cg-RX-API-DMAC7.html)
JP (1) JP7897809B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230030573A (cg-RX-API-DMAC7.html)
CN (1) CN115698059A (cg-RX-API-DMAC7.html)
AU (1) AU2021300129A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026279A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177918A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003744A1 (cg-RX-API-DMAC7.html)
IL (1) IL299207A (cg-RX-API-DMAC7.html)
MX (1) MX2022015677A (cg-RX-API-DMAC7.html)
WO (1) WO2022006305A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
US11897945B2 (en) 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2026125663A2 (en) * 2024-12-11 2026-06-18 Mabylon Ag Anti-allergen antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024164A2 (en) * 1993-04-09 1994-10-27 Schering Corporation Human monoclonal antibodies and processes and materials for making such antibodies
CN101448855A (zh) * 2006-05-18 2009-06-03 碧欧美公司 Bet v 1特异性抗体及其在预防和治疗Bet v 1诱导的疾病中的用途
WO2010089671A2 (en) * 2009-02-09 2010-08-12 Anergis S.A. Contiguous overlapping peptides for treatment of birch pollen allergy
CN108129558A (zh) * 2017-12-21 2018-06-08 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
CN110997713A (zh) * 2017-06-01 2020-04-10 瑞泽恩制药公司 抗bet v 1人抗体及其使用方法
CN121241065A (zh) * 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素a之抗體及其用途
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
US11897945B2 (en) 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
WO2025165851A1 (en) 2024-01-30 2025-08-07 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024164A2 (en) * 1993-04-09 1994-10-27 Schering Corporation Human monoclonal antibodies and processes and materials for making such antibodies
CN101448855A (zh) * 2006-05-18 2009-06-03 碧欧美公司 Bet v 1特异性抗体及其在预防和治疗Bet v 1诱导的疾病中的用途
WO2010089671A2 (en) * 2009-02-09 2010-08-12 Anergis S.A. Contiguous overlapping peptides for treatment of birch pollen allergy
CN110997713A (zh) * 2017-06-01 2020-04-10 瑞泽恩制药公司 抗bet v 1人抗体及其使用方法
CN108129558A (zh) * 2017-12-21 2018-06-08 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
CN121241065A (zh) * 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATANASIO 等: "Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response.", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 149, no. 1, 11 June 2021 (2021-06-11), pages 200 - 211 *
GEVAERT 等: "Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 149, no. 1, 11 June 2021 (2021-06-11), pages 189 - 199 *
杨朝崴: "桃过敏原表达鉴定和免疫分析", 中国博士学位论文全文数据库 农业科技辑, no. 08, 15 August 2013 (2013-08-15), pages 048 - 72 *

Also Published As

Publication number Publication date
US12583914B2 (en) 2026-03-24
WO2022006305A1 (en) 2022-01-06
KR20230030573A (ko) 2023-03-06
CL2022003744A1 (es) 2023-06-02
JP7897809B2 (ja) 2026-07-30
US11897945B2 (en) 2024-02-13
JP2023531968A (ja) 2023-07-26
BR112022026279A2 (pt) 2023-02-14
MX2022015677A (es) 2023-02-22
EP4175986A1 (en) 2023-05-10
US20240209074A1 (en) 2024-06-27
IL299207A (en) 2023-02-01
CA3177918A1 (en) 2022-01-06
AU2021300129A1 (en) 2022-12-08
US20220002394A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
US20240350625A1 (en) Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergy
US11504426B2 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
TWI755763B (zh) 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
US12583914B2 (en) Methods of treating allergy using anti-bet v 1 antibodies
US20220220211A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
WO2025165851A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
US20240092882A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
RU2833729C2 (ru) Способы лечения аллергии и усиления аллерген-специфической иммунотерапии путем введения антагониста il-4r
EA049619B1 (ru) Способы лечения аллергии с применением антител к bet v 1
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination